Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in JAMA Retrieve available abstracts of 55 articles: HTML format

Single Articles

October 2026
1. FAN Y, Liu Y, Wang Y, Ouyang Q, et al
   Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
   JAMA. 2026 Oct 23:e2621372. doi: 10.1001/jama.2026.21372.
   PubMed     Abstract available
   
   
   
2. 
   Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: Research Summary.
   JAMA. 2026 Oct 23:e2621700. doi: 10.1001/jama.2026.21700.
   PubMed    
   
   
   
3. MOSELE MF, Andre F
   Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity?
   JAMA. 2026 Oct 23. doi: 10.1001/jama.2026.22295.
   PubMed    
   
   
   
4. ANGUS DC, O'Connor MB, Young LJ
   Breast Cancer's Transformation From Terminal to Manageable: A Healthy Dialogue With Nancy E. Davidson.
   JAMA. 2026 Oct 22:e2621078. doi: 10.1001/jama.2026.21078.
   PubMed    
   
   
   July 2026
5. RUBIN R
   Breast Cancer Recommendations Fuel Debate Over Who Should Write Screening Guidelines.
   JAMA. 2026 Jul 17. doi: 10.1001/jama.2026.7095.
   PubMed    
   
   
   April 2026
6. ESSERMAN LJ, Olopade OI, Eklund M
   Screening for Breast Cancer-Reply.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1269.
   PubMed    
   
   
   
7. PESAPANE F, Cassano E
   Screening for Breast Cancer.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1263.
   PubMed    
   
   
   
8. SMIT F, Kaufman JS, Chiolero A
   Screening for Breast Cancer.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1266.
   PubMed    
   
   
   February 2026
9. PLEASANT V, Ring K
   What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors.
   JAMA. 2026 Feb 5. doi: 10.1001/jama.2026.0025.
   PubMed    
   
   
   December 2025
10. 
    Risk-Based vs Annual Breast Cancer Screening: Research Summary.
    JAMA. 2025 Dec 12:e2524865. doi: 10.1001/jama.2025.24865.
    PubMed    
    
    
    
11. ESSERMAN LJ, Fiscalini AS, Naeim A, Van't Veer LJ, et al
    Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    JAMA. 2025 Dec 12:e2524784. doi: 10.1001/jama.2025.24784.
    PubMed     Abstract available
    
    
    
12. BAXTER NN, Phillips KA
    Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.
    JAMA. 2025 Dec 12. doi: 10.1001/jama.2025.24817.
    PubMed    
    
    
    October 2025
13. PANT S
    Lesser-Known Lobular Breast Cancer on the Rise.
    JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.17524.
    PubMed    
    
    
    April 2025
14. FAN L, Shao ZM
    Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
    JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1294.
    PubMed    
    
    
    
15. PEI YY
    Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
    JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1291.
    PubMed    
    
    
    March 2025
16. HWANG ES, Hyslop T, Lynch T, Ryser MD, et al
    Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
    JAMA. 2025;333:972-980.
    PubMed     Abstract available
    
    
    
17. ANDERER S
    Trial: Less Frequent Mammograms Pose No Greater Risk After Breast Cancer.
    JAMA. 2025 Mar 7. doi: 10.1001/jama.2025.1346.
    PubMed    
    
    
    
18. LIM WH
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27807.
    PubMed    
    
    
    
19. WESTHOFF CL, Pike MC, Pearce CL
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27795.
    PubMed    
    
    
    
20. LUO P, Lin A, Miao K
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27804.
    PubMed    
    
    
    
21. SLOTH MMB, Jorgensen TSH, Nybo Andersen AM
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27798.
    PubMed    
    
    
    
22. LIBERTY AL, Rodriguez MI, Edelman A
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27810.
    PubMed    
    
    
    
23. MORCH LS, Meaidi A, Corn G
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems-Reply.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27801.
    PubMed    
    
    
    January 2025
24. HUNTER N, Hurvitz S
    Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative Breast Cancer.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26811.
    PubMed    
    
    
    
25. IGNATIADIS M, Bailey A, McArthur H, El-Abed S, et al
    Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26886.
    PubMed     Abstract available
    
    
    December 2024
26. JOENSUU H
    Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.25927.
    PubMed    
    
    
    
27. CHEN L, Li H, Zhang H, Yang H, et al
    Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560.
    PubMed     Abstract available
    
    
    November 2024
28. ANDERER S
    ACOG Now Recommends Breast Cancer Screenings Start at Age 40.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23048.
    PubMed    
    
    
    
29. ANDERER S
    Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23049.
    PubMed    
    
    
    
30. ORRALL A
    Breast Cancer Incidence Still Rising Despite Decline in Death Rates.
    JAMA. 2024 Nov 1. doi: 10.1001/jama.2024.22056.
    PubMed    
    
    
    October 2024
31. MORCH LS, Meaidi A, Corn G, Hargreave M, et al
    Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575.
    PubMed    
    
    
    September 2024
32. THORAT MA, Cuzick J, Chan AT
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15497.
    PubMed    
    
    
    
33. PETRELLI F, Ghidini A
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15491.
    PubMed    
    
    
    
34. LI C, He J, Liang W
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15488.
    PubMed    
    
    
    
35. SUN R, Wei LJ
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15494.
    PubMed    
    
    
    
36. CHEN WY, Ballman KV, Holmes MD
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reply.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15500.
    PubMed    
    
    
    
37. RYAN CE, Fasaye GA, Gallanis AF, Gamble LA, et al
    Germline CDH1 Variants and Lifetime Cancer Risk.
    JAMA. 2024;332:722-729.
    PubMed     Abstract available
    
    
    August 2024
38. HARRIS E
    More Data About Risks, Benefits Might Change Breast Cancer Screening Choice.
    JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13777.
    PubMed    
    
    
    July 2024
39. LEON-FERRE RA, Salgado R, Jonas SF
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10483.
    PubMed    
    
    
    
40. TU H, Zhang Y, You Z
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10480.
    PubMed    
    
    
    June 2024
41. RUBIN R
    Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
    JAMA. 2024;331:1877-1879.
    PubMed    
    
    
    May 2024
42. MANSON JE, Crandall CJ, Rossouw JE, Chlebowski RT, et al
    The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
    JAMA. 2024;331:1748-1760.
    PubMed     Abstract available
    
    
    
43. MANDELBLATT JS, Mainor C, Hudson BI
    The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
    JAMA. 2024;331:1709-1711.
    PubMed    
    
    
    
44. HARRIS E
    Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734.
    PubMed    
    
    
    April 2024
45. TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al
    Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766.
    PubMed     Abstract available
    
    
    
46. NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al
    Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534.
    PubMed     Abstract available
    
    
    
47. HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al
    Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844.
    PubMed     Abstract available
    
    
    
48. 
    Screening for Breast Cancer.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535.
    PubMed    
    
    
    
49. ELMORE JG, Lee CI
    Toward More Equitable Breast Cancer Outcomes.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052.
    PubMed    
    
    
    
50. CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840.
    PubMed     Abstract available
    
    
    
51. CASWELL-JIN JL, Kurian AW, Plevritis SK
    US Breast Cancer Mortality-Reply.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
    PubMed    
    
    
    
52. JATOI I
    US Breast Cancer Mortality.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
    PubMed    
    
    
    
53. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    PubMed    
    
    
    
54. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    PubMed    
    
    
    
55. LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al
    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    JAMA. 2024;331:1135-1144.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum